Drug Therapy in Lennox-Gastaut Syndrome

  • Kevin Farrell
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 497)


A logical approach to the pharmacological management of Lennox-Gastaut syndrome (LGS) is complicated by several factors. There have been few well-designed studies of antiepileptic drugs in LGS. In addition, the criteria used for the diagnosis of LGS vary between studies. The multitude of different approaches to drug treatment reflects the evidence-based vacuum in which the treatment of LGS exists. This chapter will discuss some of these issues and will describe the authors approach to drug treatment of this condition.


Valproic Acid Antiepileptic Drug Seizure Frequency Seizure Control Ketogenic Diet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aicardi, J.Epilepsy in Children2nd Edition, Raven Press, New York (1994) International Review of Child Neurology Series.Google Scholar
  2. 2.
    Aicardi, J. and Chevrie, J.J. Atypical benign epilepsy of childhoodDev. Med. Child Neurol.24 (1982) 281–292.PubMedCrossRefGoogle Scholar
  3. 3.
    Appleton, R.E. Guideline may help in prescribing vigabatrinBr. Med.d, 317 (1998) 1322.Google Scholar
  4. 4.
    Beaumanoir, A. and Dravet, C. The Lennox-Gastaut syndrome. In: J. Roger, M. Bureau, C. Dravet, F.E. Dreifuss, A. Perret, and P. Wolf (Eds.)Epileptic Syndromes in Infancy Childhood and Adolescence 2nd Edition, John Libbey Eurotext, London, England (1992) pp. 115–134.Google Scholar
  5. 5.
    Ben-Menachem, E. Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humansEpilepsia30(Suppl. 3) (1989) S12–S14.PubMedCrossRefGoogle Scholar
  6. 6.
    Bittencourt, P.R.M. and Richens, A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndromeEpilepsia22 (1981) 129–134.PubMedCrossRefGoogle Scholar
  7. 7.
    Brett, E.M. The Lennox-Gastaut syndrome: therapeutic aspects. In: E. Niedermeyer and R. Degen (Eds.)The Lennox-Gastaut SyndromeAlan R Liss Inc., New York (1988) pp. 329–339.Google Scholar
  8. 8.
    Chadwick, D., Shaw, M.D., Foy, P, Rawlins, M.D., and Turnbull, D.M. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions, JNeurol. Neurosurg. Psychiatr.47 (1984) 642–644.PubMedCrossRefGoogle Scholar
  9. 9.
    Chevrie, J.J. and Aicardi, J. Childhood epileptic encephalopathy with slow spike-wave. A statistical study of 80 casesEpilepsia13 (1972) 259–271.PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen, A.F, Land, G.S., Breimer, D.D., Yuen, W.C., Winton, C., and Peck, A.W. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humansClin. Pharmacol. Ther.4 5) (1987) 535–541.CrossRefGoogle Scholar
  11. I1.
    Connolly, M.B., Farrell, K., Karim, Y., Smith, S., and Wong, P.K.H. Video-EEG in paediatric outpatientsEpilepsia35 (1994) 477–481.PubMedCrossRefGoogle Scholar
  12. 12.
    Cull, C.A. and Trimble, M.R. Anticonvulsant benzodiazepines and performanceRoy. Soc. Med. Int. Cong. Symp. Ser.74 (1985) 121–128.Google Scholar
  13. 13.
    Depot, M., Powell, J.R., Messenheimer, J.A. Jr., Cloutier, G., and Dalton, M.J. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigineClin. Pharmacol Ther.48(4) (1990) 346–355.PubMedCrossRefGoogle Scholar
  14. 14.
    De Vivo, D.C. How to use other drugs (steroids) and the ketogenic diet. In: P.L. Morselli, C.E. Pippenger, and J.K. Penry (Eds.)Antiepileptic Drug Therapy in PediatricsRaven Press, New York (1983) pp. 137–144.Google Scholar
  15. 15.
    Dimario, F.J. and Clancy, R.R. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizuresPediatr. Neurol.4 (1988) 249–251.PubMedCrossRefGoogle Scholar
  16. 16.
    Doose, H. Myoclonic-astatic epilepsy of early childhood. In: J. Roger, M. Bureau, C. Dravet, F.E. Dreifuss, A. Perret, and P. Wolf (Eds.)Epileptic Syndromes in Infancy Childhood and Adolescence 2nd edition, John Libbey Eurotext, London, England (1992) pp. 103–114.Google Scholar
  17. 17.
    Dreifuss, F. Valproate: Toxicity. In: R.H. Levy, F.E Dreifuss, R.H. Mattson, B.S. Meldrum, and J.K. Penry (Eds.)Antiepileptic DrugsRaven Press, New York (1989) pp. 643–651.Google Scholar
  18. 18.
    Dulac, O. The use of lamotrigine in children. In: S. Johnson and F.N. JohnsonRev. Contemp. PharmacohertMarius Press (1994) pp. 133–139.Google Scholar
  19. 19.
    Dulac, O. and N’Guyen, T. The Lennox-Gastaut syndromeEpilepsia34(Supp1.7) (1993) S7–S17.PubMedCrossRefGoogle Scholar
  20. 20.
    Eeg-Olofsson, O. Treatment of epileptic disorders of children. In: P. Robb (Ed.)Epilepsy Updated: Causes and TreatmentYearbook Medical Publishers, Chicago (1980) pp. 199–213.Google Scholar
  21. 21.
    Farrell, K. Benzodiazepines in the treatment of children with epilepsyEpilepsia27 (1986) S45–S51.CrossRefGoogle Scholar
  22. 22.
    Farrell, K., Connolly, M.B., Munn, R., Peng, S., and MacWilliam, L.M. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsyPediatric Neurology16 (1997) 201–205.PubMedCrossRefGoogle Scholar
  23. 23.
    Felbamate Study Group in Lennox-Gastaut. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome)N. Engl. J. Med.328 (1993) 29–33.CrossRefGoogle Scholar
  24. 24.
    Frey, H-H. Experimental evidence for the development of tolerance to anticonvulsant drug effects. In: H-H. Frey, W. Fröscher, W.P. Koella, and H. Meinardi (Eds.)Tolerance to Beneficial and Adverse Effects of Antiepileptic DrugsRaven Press, New York (1986) pp. 7–14.Google Scholar
  25. 25.
    Gastaut, H. and Lowe, M.D. Antiepileptic properties of clobazam, a 1,5 benzodiazepine, in manEpilepsia20 (1979) 437–446.PubMedCrossRefGoogle Scholar
  26. 26.
    Gastaut, H., Roger, J., Soulayrol, R., Tassinari, C.A., Regis, H., and Dravet, C. Childhood epileptic encephalopathy with diffuse spike-waves (otherwise known as “petit mal variant”) or Lennox syndromeEpilepsia7 (1966) 139–179.CrossRefGoogle Scholar
  27. 27.
    Glauser, T.A. Preliminary observations on topiramate in pediatric epilepsiesEpilepsia38(Suppl 1) (1997) S37–S41.PubMedCrossRefGoogle Scholar
  28. 28.
    Gram, L., Sabers, A., and Dulac, O. Treatment of Pediatric Epilepsies with g-Vinyl GABA (Vigabatrin)Epilepsia(1992) S26–S29.Google Scholar
  29. 29.
    Grant, S. and Heel, R.C. Vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor controlDrugs41(6) (1991) 889–926.PubMedCrossRefGoogle Scholar
  30. 30.
    Group for the evaluation of cinromide in Lennox-Gastaut syndrome. Double-blind placebo-controlled study of cinromide in patients with Lennox-Gastaut syndromeEpilepsia30 (1989) 422–429.CrossRefGoogle Scholar
  31. 31.
    Hasaerts, D. and Dulac, O. Traitement par hydrocortisone des epilepsies generalisees secondaire de grand enfantArch. Fr. Pediatr.46 (1989) 635–639.PubMedGoogle Scholar
  32. 32.
    Jeavons, P.M., Clark, J.E., and Maheshwari, M.C. Treatment of the generalized epilepsies of childhood and adolescence with sodium valproate (Epilim)Dev. Med. Child Neurol.19 (1977) 9–25.PubMedCrossRefGoogle Scholar
  33. 33.
    Kinsman, S.L., Vining, E.P.G., Quaskey, S.A., Mellits, D., and Freeman, J.M. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 casesEpilepsia33 (1992) 1132–1136.PubMedCrossRefGoogle Scholar
  34. 34.
    Kramer, L.D. and Reife, R.A. Topiramate. In: J.E. Jr. and T.A. Pedley (Eds.)Epilepsy: a comprehensive textbookLippincott-Raven Publishers, Philadelphia (1997) pp. 1593–1598.Google Scholar
  35. 35.
    Livingston, J.H., Beaumont, D., Arzimanoglou, A., and Aicardi, J. Vigabatrin in the treatment of epilepsy in childrenBr. J. Clin. Pharmacol27 (1989) 1095–112S.Google Scholar
  36. 36.
    Lombroso, C.T. and Forsythe, I. A long-term follow-up of acetazolamide in the treatment of epilepsyEpilepsia1 (1960) 493–500.PubMedCrossRefGoogle Scholar
  37. 37.
    Luna, D., Dulac, O., Pajot, N., and Beaumont, D. Vigabatrin in the treatment of childhood epilepsies: A single-blind placebo-controlled studyEpilepsia30(4) (1989) 430–437.PubMedCrossRefGoogle Scholar
  38. 38.
    Motte, J., Trevathan, E., Arvidsson, J.F., Barrera, M.N., Mullens, E.L., and Manasco, P. Lamotrigine for generalized seizures associated with Lennox-Gastaut syndromeN. Engl. J. Med337 (1997) 1807–1812.PubMedCrossRefGoogle Scholar
  39. 39.
    Munn, R.I. and Farrell, K. Open study of Clobazam in refractory epilepsyPediatr. Neurol.9 (1993) 465–469.PubMedCrossRefGoogle Scholar
  40. 40.
    Niedermeyer, E. The Lennox-Gastaut syndrome: Clinical Description and Diagnosis. In: W.M. Burnham, P.L. Carlen, and P.A. Hwang (Eds.)Intractable Seizures: Diagnosis and TherapyKluwer Academic/Plenum Publishers, New York (2000).Google Scholar
  41. 41.
    O’Donohoe, N.V.Epilepsies of Childhood2nd Ed., Butterworths, London (1985).Google Scholar
  42. 42.
    Papini, M., Pasquinelli, A., Armellini, M., and Orlandi, D. Alertness and incidence of seizures in patients with Lennox-Gastaut syndromeEpilepsia25 (1984) 161–167.PubMedCrossRefGoogle Scholar
  43. 43.
    Pisani, E. Pharmacokinetics of lamotrigine. In: E.H. Reynolds (Ed.)Lamotrigine-a new advance in the treatment of epilepsyRoyal Society of Medicine Services, London (1993).Google Scholar
  44. 44.
    Rey, E., Pons, G., and Olive, G. VigabatrinClin. Pharmacokinet.12(4) (1992) 267–278.Google Scholar
  45. 45.
    Richens, A. Pharmacology and clinical pharmacology of vigabatrin, J.Child Neurol.5 (1991) 2S7–02S1.CrossRefGoogle Scholar
  46. 46.
    Richens, A. Safety of lamotrigineEpilepsia35(Suppl. 5) (1994) S37–S40.PubMedCrossRefGoogle Scholar
  47. 47.
    Roger, J., Dravet, C., and Bureau, M. The Lennox-Gastaut syndromeCleve. Clin. J. Med.56 (1989) S172–S180.PubMedGoogle Scholar
  48. 48.
    Sachdeo, R.C., Glauser, T.A., Ritter, E, Reife, R., Lim, P, and Pledger, G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndromeNeurology52 (1999) 1882–1887.PubMedCrossRefGoogle Scholar
  49. 49.
    Sackallares, J.C., Lee, S.I., and Dreifuss, F.E. Stupor following administration of valproic acid to patients receiving other antiepileptic drugsEpilepsia20 (1979) 697–703.CrossRefGoogle Scholar
  50. 50.
    Schlumberger, E., Chavez, F., Palacios, L., Rey, E., Pajot, N., and Dulac, O. Lamotrigine in treatment of 120 children with epilepsyEpilepsia35 (1994) 359–367.PubMedCrossRefGoogle Scholar
  51. 51.
    Schmidt, D. How to use benzodiazepines. In: P.L. Morselli, C.E. Pippenger, and J.K. Penry (Eds.)Antiepileptic drug therapy in paediatricsRaven Press, New York (1983) pp. 271–278.Google Scholar
  52. 52.
    Schmidt, D. Adverse effects of valproateEpilepsia25(Suppl. 1) (1984) S44–S49.PubMedCrossRefGoogle Scholar
  53. 53.
    Schmidt, D. Benzodiazepines-an update. In: T.A. Pedley and B.S. Meldrum (Eds.)Recent Advances in EpilepsyChurchill Livingstone, Edinburgh (1985) pp. 125–135.Google Scholar
  54. 54.
    Sherwin, A.L. Ethosuximide: Clinical use. In: R.H. Levy, R.H. Mattson, and B.S. Meldrum (Eds.)Antiepileptic Drugs4`h Ed., Raven Press, New York (1995) pp. 667–673.Google Scholar
  55. 55.
    Shorvon, S.D. Safety of topiramate: adverse events and relationships to dosingEpilepsia37(Suppl 2) (1996) S18–S22.PubMedCrossRefGoogle Scholar
  56. 56.
    Tassinari, C.A., Dravet, C., Roger, J., Cano, J.P., and Gastaut, H. Tonic status epilepticus precipitated by intravenous benzodiazepines in five patients with Lennox-Gastaut syndromeEpilepsia13 (1972) 421–435.PubMedCrossRefGoogle Scholar
  57. 57.
    Tavernor, S.J., Wong, I.C., Newton, R., and Brown, S.W. Rechallenge with lamotrigine after initial rashSeizure4 (1995) 67–71.PubMedCrossRefGoogle Scholar
  58. 58.
    Theodore, WH., Jensen, P.K., and Kwan, R.M.F. Felbamate: clinical use. In: R.J. Levy, R.H. Mattson, and B.S. Meldrum (Eds.)Antiepileptic Drugs4’ Ed., Raven Press, New York (1995) pp. 817–822.Google Scholar
  59. 59.
    Timmings, P.L. and Richens, A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndromeEur. Neural.32 (1992) 305–307.CrossRefGoogle Scholar
  60. 60.
    Vining, E.P. The Ketogenic Diet. In: W.M. Burnham, P.L. Carlen, and P.A. Hwang (Eds.)Intractable Seizures: Diagnosis and TherapyKluwer Academic/Plenum Publishers, New York (2000).Google Scholar
  61. 61.
    Williams, L.H.P., Reynolds, R.P., and Emery, J.L. Pancreatitis during sodium valproate treatment.Arch. Dis. Child58 (1983) 543–544.PubMedCrossRefGoogle Scholar
  62. 62.
    Wyllie, E., Wyllie, R., Cruse, R.P., Erenberg, G., and Rothner, A.D. Pancreatitis associated with valproic acid therapyAm. J Dis. Child138 (1984) 912–914.PubMedGoogle Scholar
  63. 63.
    Yamatogi, Y, Ohtsuka, Y, Ishida, T., Ichiba, N., Ishida, S., Miyake, S., Oka, E., and Ohtahara, S. Treatment of the Lennox syndrome with ACTH: a clinical and electroencephalographic studyBrain Dev.1 (1979) 267–276.PubMedCrossRefGoogle Scholar
  64. 64.
    Yuen, A.W.C., Land, G., Weatherley, B.C., and Peck, A.W. Sodium valproate acutely inhibits lamotrigine metabolism, Br.J Clin. Pharmacol.33 (1992) 511–513.Google Scholar
  65. 65.
    Yuen, A.W.C. and Peck, A.W. Lamotrigine pharmacokinetics: oral and i.v. infusion in manBr. J. Clin. Pharmacol26 (1988) 242.Google Scholar
  66. 66.
    Yuen, A.W.C. and Rafter, J.E.W. Lamotrigine (Lamictal) as add-on therapy in pediatric patients with treatment-resistant epilepsy: an overviewEpilepsia33(Suppl. 3) (1992) 82–83.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Kevin Farrell
    • 1
  1. 1.Neurology British Columbia’s Children’s HospitalVancouver

Personalised recommendations